Long‐Term Follow‐Up After Direct‐Flow Transcatheter Aortic Valve Implantation: A Single Center Experience
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Dan M Prunea und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Aortic Valve. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Aims
Valve degeneration after DirectFlow implantation poses a challenge for valve‐in‐valve procedures due to its fragile polymeric structure and embolization risk. This study analyzes long‐term follow‐up of patients who underwent TAVI with DF to understand valve degeneration tendencies.
Methods
In this single‐center registry, we included all patients who underwent DF implantation in our center. Clinical characteristics and echocardiographic parameters were assessed at baseline and during the latest follow‐up. Long‐term overall survival was analyzed. Outcome data was compared with a matched cohort of patients who underwent TAVI with other commercial devices during the same period.
Results
From 2014 to 2017, 67 patients with significant aortic stenosis were treated with DF; 36 (54%) were male, mean age 83 ± 7 years. Left ventricular ejection fraction was 50 ± 13% with a mean gradient of 46 ± 15 mmHg. Post‐procedural echocardiography showed a mean gradient of 16 ± 8 mmHg, markedly higher than the reference group (8 ± 3 mmHg; p < 0.01). This residual gradient showed no progression during follow‐up at 20 [9; 39] months (16 ± 9 mmHg; p = 0.52). Overall survival was comparable between DF and the reference group at 12 months (6% vs. 4%, HR 1.37, 95% CI 0.31–6.02) and maximal follow‐up of 39 ± 25 months (31% vs. 25%, HR 1.44, 95% CI 0.76–2.73).
Conclusions
According to this single center experience, DF devices resulted in higher residual gradients; however, no signs of faster degeneration or worse long‐term outcomes were observed compared to other devices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria.
- "Niculae Stăncioiu" Heart Institute, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
- Doctoral School of Clinical Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary.
- Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
ORCID-Profile: Dan M Prunea, Alexandru Achim, Sadeek S Kanoun Schnur
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Prunea, D. M., Geissler, R., Achim, A., Stark, C., Kanoun Schnur, S. S., Strobl, B., Bugger, H., Luha, O., Zirngast, B., Schmidt, A., Zirlik, A., & Toth, G. G. (2025). Long‐Term Follow‐Up After Direct‐Flow Transcatheter Aortic Valve Implantation: A Single Center Experience. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31647
Vancouver
Prunea DM, Geissler R, Achim A, Stark C, Kanoun Schnur SS, Strobl B, et al. Long‐Term Follow‐Up After Direct‐Flow Transcatheter Aortic Valve Implantation: A Single Center Experience. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31647
BibTeX
@article{Prunea2025,
author = {Prunea, Dan M and Geissler, Raffael and Achim, Alexandru and Stark, Cosima and Kanoun Schnur, Sadeek S and Strobl, Brigitte and Bugger, Heiko and Luha, Olev and Zirngast, Birgit and Schmidt, Albrecht and Zirlik, Andreas and Toth, Gabor G},
title = {Long‐Term Follow‐Up After Direct‐Flow Transcatheter Aortic Valve Implantation: A Single Center Experience},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31647}
}
EUVIMED